Abstract:e13002 Background: Next generation sequencing (NGS) technologies have already shown numerous advances to revolutionize our understanding of cancer genomic profiling and improve cancer treatments. There have been many NGS data analysis tools available for identification of different genomic alternations including short insertion and deletion (short indel, < 25 bp in general). However, detection of > 100 bp large indel (L-indel) from short reads (generally < 200 bp) remains a huge challenge. L-indels identified in genes like MET and FLT3 have proven a critical implication in cancer treatments. Moreover, there is an urgent need for an algorithm to validate L-indels generated by genomic modification systems like ZFN, TALENs and CRISPR/Cas9. Methods: A novel algorithm was developed for calling L-indels in targeted sequencing data as following: raw reads were first filtered by selecting high-quality ones and correcting wrong bases; a chunk of contig (unitig) was then assembled and aligned to reference genome; lastly, break point information was collected and L-indels were calculated. The algorithm was applied on the reads generated from NA12878 cell line and FFPE samples collected in our lab respectively on the Illumina platform. Validation were performed by PCR and Sanger sequencing. Results: 22 novel exonic L-indels (17 deletions and 5 insertions) were identified with a median size of 1,616 bp (range: 25-6,684 bp) from NA12878 sequencing data and 100% successfully confirmed by Sanger sequencing. In addition, 6 out of 9 reported L-indels were also found with the rest awaiting for further exploration. Strikingly, a 2,446 bp deletion on MSH6, encodes an important component in mismatch repair (MMR) system, was detected on a FFPE sample of a lung cancer adenocarcinoma, which prompted to consideration of MMR deficiency otherwise. Conclusions: We have developed and validated a novel and accurate method for NGS large indels detection dedicated for targeted sequencing data in clinical cancer setting. Equipment of this method will greatly increase the capability of comprehensively understanding genomic alterations from a single NGS-based assay, and provide more information for potential clinical use.

Analysis of error profiles in deep next-generation sequencing data

[A consensus on the standardization of the next generation sequencing process for the diagnosis of genetic diseases (3) - Data analysis].

Evaluation of false positive and false negative errors in targeted next generation sequencing

DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly

Chasing Sequencing Perfection: Marching Toward Higher Accuracy and Lower Costs

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

A Novel Approach to Detect Large Indels from Targeted Sequencing Data in Clinical Cancer Setting

High efficiency error suppression for accurate detection of low-frequency variants

Reliable multiplex sequencing with rare index mis-assignment on DNB-based NGS platform

Hidden Biases in Germline Structural Variant Detection.

Turn ‘noise’ to signal: accurately rectify millions of erroneous short reads through graph learning on edit distances

How Error Correction Affects PCR Deduplication: A Survey Based on UMI Datasets of Short Reads

Impact of genotyping errors on statistical power of association tests in genomic analyses: A case study.

Too many needles in this haystack: algorithms for the analysis of next generation sequence data

Biases and errors on allele frequency estimation and disease association tests of next-generation sequencing of pooled samples.

Evaluation of next generation sequencing platforms for population targeted sequencing studies

Application of Next-Generation Sequencing in the Detection of Low-Abundance Mutations.

Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Detection of ultra-rare mutations by next-generation sequencing

Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing